On October 9th, THDB held a performance briefing for the first half of 2025, stating that the domestic insulin market will continue to develop steadily over the next three years. The company is continuously developing new products, such as ultra-fast-acting insulin, degludec insulin liraglutide injection, and GLP-1/GIP dual-target receptor agonists, as well as expanding into new therapeutic areas, such as weight loss and gout, to continuously explore new market space and promote the company's long-term high-quality development
